Anti-Inflammatory Effect of Statins in the Human Endotoxin Model

Status Completed

Clinical Trial Summary

The purpose of this study is to determine the effects of HMG-CoA reductase inhibitor pretreatment on inflammation and coagulation activation in human endotoxemia.

Clinical Trial Description

The beneficial effect of lipid lowering in cardiovascular disease is well established. Statin potently reduce elevated cholesterol levels but also exert pleiotropic other effects such as improvement of inflammation-induced vascular dysfunction, upregulation of endothelial nitric oxide synthase, yield antiinflammatory and antioxidant properties and lower tissue factor (TF) expression on peripheral blood mononuclear cells (PB-MNC) in vivo. The mechanism of action for these effects remains unclear, but is already seen after short term treatment and was independent of cholesterol reduction. Following endotoxin administration to healthy humans, the systemic response includes the activation of inflammation by cytokines, mainly IL-1, IL-6, THF-α and INF-γ, activation of the clotting system with enhanced thrombin generation, and vascular dysfunction, as demonstrable by an impaired response to vasoconstrictors. Low dose endotoxemia therefore serves as an adequate model for acute inflammation and the interaction of the three systems.

The goal of this study is to determine the effect of HMG-CoA reductase inhibitor pretreatment on inflammation and coagulation activation in human endotoxemia and to investigate if anti-inflammatory effects are similar between two different statins. Further, we plan to study genome-wide effects on the leukocyte transcriptome induced by (i) statin pretreatment, (ii) low-dose endotoxemia, and (iii) the anti-inflammatory effects if the statins.

The study will be carried out as a randomized placebo controlled double-blind threeway crossover three period study. Subjects will receive three treatment periods (Day 1 - Day 5) in randomized order consisting of 5 days oral Simvastatin (80 mg/day), 5 days oral Rosuvastatin (40 mg/day) and 5 days adequate placebo. On Day 5 of each study period, subjects will receive LPS (2 ng/kg i.v.). Inflammatory protein expression and coagulation activation will be assessed on Day 1 and Day 5 of each period. Washout-time between treatment periods will be ≥6 weeks. ;

Study Design

Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Crossover Assignment, Masking: Double-Blind, Primary Purpose: Treatment

Related Conditions & MeSH terms

Endotoxemia

Clinical Trial Details

NCT number	NCT00309374
Study type	Interventional
Source	Medical University of Vienna
Contact
Status	Completed
Phase	Phase 1
Start date	March 2006
Completion date	July 2006

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT04117802` - Effects of Maple Syrup on Gut Microbiota Diversity and Metabolic Syndrome	N/A
Completed	`NCT02922673` - The Effects of Acetylsalicylic Acid on Immunoparalysis Following Human Endotoxemia	N/A
Completed	`NCT01766414` - In Vivo Effects of C1-esterase Inhibitor on the Innate Immune Response During Human Endotoxemia - VECTOR II	Phase 3
Completed	`NCT04130321` - Demonstration of the Prebiotic-like Effects of Camu-camu Consumption Against Obesity-related Disorders in Humans	N/A
Completed	`NCT02612480` - Ticagrelor in Human Endotoxemia Response to Human Endotoxemia	N/A
Completed	`NCT01474629` - Probiotic Sport Study	N/A
Completed	`NCT00246714` - Pathophysiology and Clinical Relevance of Endotoxin Tolerance in Humans	Phase 1
Recruiting	`NCT06147440` - Different Dietary Patterns	N/A
Recruiting	`NCT03901807` - Safety and Efficacy of Polymyxin B Hemoperfusion (PMX) for Endotoxemic Septic Shock in a Randomized, Open-Label Study	N/A
Completed	`NCT03754504` - Effects of Cranberry Powder Supplements on Gut Microbiota Diversity and Metabolic Syndrome	N/A
Completed	`NCT03800277` - Effect of Cranberry and Agaves Extract on Microbiota and Intestinal Health	N/A
Completed	`NCT00785018` - In Vivo Effects of C1-esterase Inhibitor on the Innate Immune Response During Human Endotoxemia	N/A
Recruiting	`NCT00413348` - Type 2 Diabetes and the Effect of Probiotics	N/A
Recruiting	`NCT00413465` - Study of Renal Blood Flow During Human Endotoxemia	N/A
Completed	`NCT00412906` - Study of Gene Activity in Fat and Muscle in Diabetics and Healthy Controls	N/A
Completed	`NCT05752968` - Elevated Levels of Antibodies to Endotoxin Core in Hemodialysis Patients With Peripheral Artery Disease
Completed	`NCT01374711` - The Effects of Immunostimulation With GM-CSF or IFN-y on Immunoparalysis Following Human Endotoxemia	N/A
Completed	`NCT00916448` - The Effects of Atazanavir-induced Hyperbilirubinemia During Human Endotoxemia	N/A
Completed	`NCT00332267` - Cerebral Blood Flow and Metabolism During Hypoxia and Endotoxemia	N/A
Completed	`NCT03482284` - Effect of Monosaccharides on Intestinal Barrier Function	N/A

Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.